Erste Group Bank Forecasts Novartis FY2026 Earnings

Novartis AG (NYSE:NVS) – Stock analysts at Erste Group Bank lowered their FY2026 earnings per share estimates for shares of Novartis in a research note issued to investors on Wednesday, October 21st. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $9.16 for the year, down from their prior forecast of $9.24. The consensus estimate for Novartis’ current full-year earnings is $8.91 per share. Erste Group Bank also issued estimates for Novartis’ FY2027 earnings at $9.81 EPS.

A number of other equities analysts have also recently commented on NVS. Royal Bank Of Canada began coverage on Novartis in a report on Tuesday, September 8th. They set a “sector perform” rating for the company. The Goldman Sachs Group reaffirmed a “sell” rating on shares of Novartis in a report on Monday, September 21st. Deutsche Bank Aktiengesellschaft reiterated a “neutral” rating on shares of Novartis in a research report on Thursday, September 17th. Bank of America reissued a “buy” rating on shares of Novartis in a research note on Tuesday, September 8th. Finally, HSBC upgraded shares of Novartis from a “reduce” rating to a “hold” rating and raised their target price for the company from $123.00 to $136.00 in a research report on Thursday, September 10th. Six research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $145.60.

Novartis Stock Performance

NYSE NVS opened at $156.81 on Wednesday. The business has a fifty day moving average price of $148.28 and a two-hundred day moving average price of $151.54. Novartis has a fifty-two week low of $121.57 and a fifty-two week high of $170.46.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.25 by $0.21. The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.53 billion. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.25 EPS.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in NVS. Bank of America Corp DE boosted its position in Novartis by 9.1% during the 1st quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock worth $758,067,000 after buying an additional 413,778 shares during the period. Envestnet Asset Management Inc. increased its position in Novartis by 0.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 2,330,979 shares of the company’s stock valued at $365,308,000 after acquiring an additional 19,595 shares during the period. Janus Henderson Group PLC raised its stake in shares of Novartis by 1.9% during the first quarter. Janus Henderson Group PLC now owns 2,275,938 shares of the company’s stock valued at $347,649,000 after acquiring an additional 41,520 shares during the last quarter. WCM Investment Management LLC bought a new position in shares of Novartis during the first quarter valued at $220,004,000. Finally, Sei Investments Co. lifted its holdings in shares of Novartis by 9.6% during the first quarter. Sei Investments Co. now owns 619,274 shares of the company’s stock worth $94,594,000 after purchasing an additional 54,262 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis News Roundup

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis reported third-quarter EPS of $2.46, above the $2.25 analyst consensus, while revenue reached approximately $15.03 billion versus expectations of $14.53 billion. Sales increased 4.4% year over year. Novartis quarterly earnings report
• Positive Sentiment: The company raised its 2026 core operating-income outlook, citing productivity gains and continued demand for newer medicines. Novartis maintained its sales-growth forecast as Kisqali, Kesimpta and Scemblix helped offset generic competition. Novartis Q3 earnings and outlook
• Positive Sentiment: Phase 3 data for remibrutinib in multiple sclerosis showed lower relapse rates, with no Hy’s Law liver-safety cases reported, supporting the potential of the company’s development pipeline. Remibrutinib multiple sclerosis trial results
• Neutral Sentiment: NVS has moved above its 200-day moving average, a technical signal that may reinforce bullish sentiment, although it does not change the company’s fundamentals. Novartis shares cross above 200-day moving average
• Negative Sentiment: Reported profit declined because of a roughly $1.9 billion impairment charge, higher expenses and setbacks in recent clinical trials. Investors are also monitoring Kisqali, Novartis’ largest revenue contributor, which fell short of expectations. Novartis earnings caveats

Novartis Company Profile

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.